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http://www.trialsjournal.com/content/15/1/332STUDY PROTOCOL Open AccessSimvastatin to modify neutrophil function in older
patients with septic pneumonia (SNOOPI): study
protocol for a randomised placebo-controlled trial
Hannah Greenwood, Jaimin Patel, Rahul Mahida, Qian Wang, Dhruv Parekh, Rachel CA Dancer, Heena Khiroya,
Elizabeth Sapey and David R Thickett*Abstract
Background: Community-acquired pneumonia (CAP) is considered the leading cause of death from infectious disease
in developed countries, while complications of CAP - sepsis being the most common and challenging - increase the
risk of mortality. During the progression of sepsis, a state of neutrophil ‘paralysis’ develops resulting in the impairment
of neutrophil anti-microbial functions including: chemotaxis, production of reactive oxygen species, and formation of
neutrophil extracellular traps (NETs). Mechanisms underlying defective neutrophil function remain elusive although NET
formation has been implicated in the immunosuppression and increased rates of sepsis observed in neonates. There is,
however, increasing evidence that statins are able to modulate neutrophil function in sepsis as several systematic
reviews have concluded that statins have a role in improving infection-related outcomes and mortality while,
in vitro, statins have also been shown to boost NET formation in healthy individuals.
Methods/design: The ‘SNOOPI’ trial is a phase 4, randomised placebo-controlled trial. The aim of this study is to
determine whether oral treatment with simvastatin compared to placebo optimises neutrophil anti-microbial functions
in elderly patients with septic pneumonia improving patient outcomes in the elderly. The primary outcome will be
NET production within 72 to 96 hours of treatment with simvastatin or placebo measured in response to a number
of inflammatory mediators, including IL8, f-Met-Leu-Phe and lipopolysaccharide. Secondary outcomes include neutrophil
migratory capacity; reactive oxygen species production; neutrophil phagocytic capacity; safety and tolerability of
simvastatin administration within this patient group; biological markers of neutrophil activation, the inflammatory
response, alveolar epithelial and endothelial injury; systemic endothelial function biomarkers and pulmonary extracellular
matrix degradation. This study aims to recruit 60 patients admitted into Queen Elizabeth Hospital Birmingham
NHS-Foundation Trust.
Discussion: This study will investigate the ability of in vivo simvastatin therapy to modulate neutrophil anti-microbial
functions in CAP-associated sepsis.
Trial registration: EudraCT number: 2012-003343-29 (Trial Registered: 26 November 2012).
Keywords: Neutrophils, Sepsis, Pneumonia, Simvastatin, Healthy AgeingBackground
Community-acquired pneumonia (CAP) is considered
the leading cause of death from infectious disease in de-
veloped countries. Increased mortality is associated with
systemic manifestations and complications of CAP, with
sepsis being the most common and challenging. The* Correspondence: d.thickett@bham.ac.uk
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article, unless otherwise stated.incidence of sepsis increases with age, while age is also a
predictor of outcome in patients with pneumonia [1].
Sepsis is characterised by a state of systemic immune
dysregulation and coagulopathy produced by invasive
microorganisms and/or their microbial products, such
as lipopolysaccharide (LPS). The initial cytokine storm
and systemic inflammatory response syndrome (SIRS) is
followed by a compensatory anti-inflammatory response
which leads to a state of significant immuno-paralysis.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and subsequent development of acute lung injury (ALI),
multi-organ dysfunction (MODS) and death [2,3].
Neutrophils constitute our main immune defence against
microbial infection by rapidly migrating to sites of infection
and/or inflammation. In a process known as chemotaxis,
neutrophils are able to sense and subsequently respond to
shallow gradients of chemoattractants formed of chemo-
tactic peptides, including cytokines, bacterial products and
complement proteins [4]. Once at the site of infection,
neutrophils act to eliminate any foreign material in an
effort to prevent widespread tissue damage and ultim-
ately resolve infection. During the progression of sepsis,
a state of neutrophil ‘paralysis’ develops resulting in the
impairment of neutrophil anti-microbial functions in-
cluding: chemotaxis, production of reactive oxygen species
(ROS), and formation of neutrophil extracellular traps
(NETs) [5]. Unable to contain the infection, widespread
dissemination of pathogenic material occurs throughout
the host, augmenting inflammation and leading to the
development of ALI and MODS [6]. Secondary to the
development of ALI and MODS, this immune paralysis or
chronic immunosuppression leads to an increased risk of
secondary infections further exacerbating the increased
risk of mortality.
Mechanisms underlying defective neutrophil function
remain elusive although NET formation has been impli-
cated in the immunosuppression and increased rates of
sepsis seen in neonates [7], while other studies suggest
NETs may exaggerate endothelial damage [8,9]. The
term NETs refers to the formation of extracellular fi-
bres composed of de-condensed chromatin laden with
anti-microbial proteins. Although phenotypically and
functionally distinct from apoptosis, ‘NETosis’ does re-
sult in cell death; however, this allows neutrophils to
exert their anti-microbial functions beyond their typical
lifespan [10].
To date, there are no studies that specifically look at
NET formation in CAP-associated sepsis. There is, how-
ever, increasing evidence that statins are able to modu-
late neutrophil function in sepsis with a recent study
demonstrating the ability of statins to reduce the neutro-
phil infiltrate following LPS challenge in bronchoalveolar
lavage fluid taken from patients receiving simvastatin
prior to challenge [11]. Furthermore, the reduction in
neutrophil counts was not associated with a decrease
in pro-inflammatory mediator expression, suggesting it
reflects a reduced neutrophil response or increased neu-
trophil apoptosis [11]. Statins inhibit 3-hydroxy-3 meth-
ylglutaryl coenzyme A reductase, a rate-limiting enzyme
in the biosynthesis of cholesterol, and have been shown to
exert numerous effects in addition to their lipid-lowering
properties including potentially anti-inflammatory and im-
munomodulatory effects [1]. Several systematic reviewshave concluded that statins have a role in improving
infection-related outcomes and mortality; however, most
of this evidence is limited to retrospective and prospective
observational studies [12,13]. In vitro, statins have also
been shown to boost NET formation in healthy individuals
with the consequent elimination of bacteria - an effect
which could therefore be an important determinant of
outcome in patients with CAP-associated sepsis [14].
Impaired neutrophil chemotaxis in the elderly
Neutrophils from healthy elderly donors demonstrate
features of immune-paralysis that resemble those seen
in patients with sepsis: healthy elderly patients (over
60 years) demonstrate defective directional migration
(chemotaxis) and overall accuracy (chemotactic index)
whilst maintaining their speed of migration (chemokinesis)
when migrating towards IL8 and the bacterial protein
f-Met-Leu-Phe (fMLP) [15].
Statins and sepsis
The ASEPSIS trial, a phase II randomised controlled
trial, demonstrated that acute administration of atorva-
statin reduces the progression of sepsis to severe sepsis
[16]. These changes were not associated with systemic
levels of cytokines or chemokines in contrast to other
reported studies suggesting the cellular effects of statins
may be more important than modulation of systemic
mediators.
Community-acquired pneumonia-associated sepsis and
neutrophil extracellular traps
During the early stages of CAP-associated sepsis, NET
production is suppressed with improvements occurring
during resolution. In addition, NET release was signifi-
cantly lower in CAP patients who meet the criteria for
severe sepsis. Taken together these data suggest that
neutrophil function is a feature of CAP-associated sepsis,
especially in the elderly, and that statin therapy may
have potential to restore the defects in these neutrophils
both in vivo and in vitro.
In light of these data, we hypothesise that the in-
creased incidence and poorer outcomes observed in the
elderly population in relation to pneumonia and sepsis
may be due to defective neutrophil function, and that
restoration of these functions may therefore improve
outcome, especially in the elderly. The SNOOPI trial
therefore aims to determine whether oral treatment with
simvastatin optimises neutrophil anti-microbial func-
tions in elderly patients admitted into Queen Elizabeth
Hospital Birmingham (QEHB) with septic pneumonia,
improving patient outcomes in the elderly. Alterations in
neutrophil function will be related to clinical outcome,
disease-relevant severity scores and biomarkers present
in blood and urine.
Table 1 Surviving Sepsis Campaign Guideline definitions
of sepsis
Condition Definition
Sepsis SIRS plus new-suspected infection
Severe sepsis Sepsis plus sepsis-induced organ dysfunction
Organ dysfunction Sepsis-induced hypotension
Lactate > normal laboratory results
Urine output <0.5 mL/kg/hour for >2 hours
despite adequate fluid resuscitation
ALI with PaO2/FiO2 < 250 in the absence of
pneumonia as infection source
ALI with PaO2/FiO2 < 200 in the presence
of pneumonia as infection source
Creatinine >176.8 mmol/L
Bilirubin >34.2 mmol/L
Platelet count >100,000/mm3
Coagulopathy (INR >1.5)
Septic shock Severe sepsis plus hypotension not reversed
by fluid resuscitation
ALI, acute lung injury; FiO2, fraction of inspired oxygen; INR, International
normalised ratio; PaO2, partial pressure of oxygen in blood; SIRS, systemic
inflammatory response syndrome.
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Trial approvals and conduct
The trial is approved by Yorkshire and Humber Ethics
Committee (REC 12/YH/0375) and is registered on the
European Clinical Trials Database (EudraCT Number:
2012-003343-29). The trial sponsor is the University of
Birmingham (Reference: RG_12-179). The trial is funded
by the British Lung Foundation (BLF reference LT/12) and
will be carried out in accordance with the principles of the
International Conference on Harmonisation Good Clinical
Practice guidelines, applicable UK legislation and standard
operating procedures of the Respiratory Research Group
at the University of Birmingham. Results of the trial will
be reported in accordance with consolidated Standards of
Reporting Trials 2010 guidelines [17].
Outcome measures
Primary outcome
The primary outcome will be NET production within 72
to 96 hours of treatment with simvastatin or placebo,
measured in response to a number of inflammatory me-
diators including IL8, fMLP and LPS and using phorbol-
12-myristate-13-acetate as a positive control [18] (for
full methods, see Additional file 1).
Secondary outcomes
Secondary outcomes of this trial include parameters de-
scribing neutrophil migratory capacity; ROS production;
neutrophil phagocytic capacity; safety and tolerability
of simvastatin administration within this patient group;
biological markers of neutrophil activation (for example,
myeloperoxidase), the inflammatory response (for example,
IL6), alveolar epithelial and endothelial injury (for example,
von Willebrand factor), and systemic endothelial function
biomarkers (for example, albumin:creatinine ratio); pul-
monary extracellular matrix (ECM) degradation and turn-
over of peptide; and, finally, the relationship of baseline
and changes in parameters described above to clinical rele-
vant outcomes (survival, development of organ failure,
admission onto intensive therapy unit, sequential organ
failure assessment score, ventilator-free days and muscle
wastage during the inpatient stay). These assessments will
be made at baseline, on days 4 and 7, and in convalescent
samples.
Neutrophil migratory capacity will be measured using
a modified Dunn chamber as described previously [15,19];
neutrophil ROS production will be measured using a
luminol-based assay and phagocytic capacity measured
by flow cytometry. Plasma indices of neutrophil activa-
tion, the inflammatory response and alveolar epithelial
and endothelial injury will be measured by enzyme-
linked immunosorbent assay, and systemic endothelial
function biomarkers and pulmonary ECM degradation
will be measured in urine collected from an indwellingurinary catheter (for full methods, see Additional file
1). These assessments will be made at baseline, on
days 4 and 7, and in convalescent samples (≥6 weeks
post-discharge).
Eligibility criteria
Patients will be eligible for the trial if they fulfil the
following criteria:
 Aged over 60 years.
 Meet the British Thoracic Society guidelines for
diagnosis of CAP, namely symptoms and signs
consistent with an acute lower respiratory tract
infection associated with radiographic shadowing
for which there is no other explanation [20].
Signs and symptoms include three or more of
the following: cough, sputum production,
breathlessness, pleuritic chest pain, haemoptysis,
fever, headache, signs consistent with pneumonia
on chest auscultation.
 CAP patients will also need to meet the criteria for
sepsis based on the standard definitions as published
in the 2008 Surviving Sepsis Campaign Guidelines
[21] as illustrated in Table 1.
 All sepsis and pneumonia criteria must occur within
the same 24-hour period (sepsis is defined as evidence
of infection plus SIRS; see Table 2).
 Patients must be enrolled within 48 hours of
admission to hospital.
Table 2 Systemic inflammatory response syndrome
diagnostic criteria
Criteria:
Two or more of the
following:
Fever of ≥38°C or ≤36°C
Heart rate ≥90 beats per minute
Respiratory rate ≥20 breaths per minute or
PaCO2 levels ≥32 mmHg
Abnormal white blood cell count (>12,000/μl
or <4,000/μl or >10% bands)
PaCO2, partial pressure of carbon dioxide in
blood.
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excluded from the study:
 More than 48 hours from admission at time of consent
 Current or recent statin use within 1 month.
 Known prior myositis.
 Creatinine kinase >10 times upper limit of normal
range*.
 Transaminases (alanine aminotransferase/aspartate
aminotransferase) >8 times upper limit of normal
range*.
 Severe renal impairment (creatinine clearance
<30 ml/min) not receiving renal replacement therapy.
 Patients currently receiving ongoing and sustained
treatment with any of the following: itraconazole,
ketoconazole, HIV protease inhibitors, nefazodone,
ciclosporin, amiodarone, verapamil or diltiazem,
Fibric acid derivatives (except fenofibrate), danazol.
 A family history of muscular disorders.
 Known HIV or hepatitis B/C infection.
 Contraindication to enteral drug administration
(either orally or via nasogastic tube; for example,
patients with mechanical bowel obstruction).
 Known participation in other investigational
medicinal product (IMP) trials within 30 days.
 Consent/relative or advocate assent declined.
 Treatment withdrawal imminent within 24 hours.
 Non-English speaking patients or those who do not
adequately understand verbal or written information
unless an interpreter is available.
 Immunosuppression due to corticosteroid or other
immunosuppressant use.
(*If creatinine kinase, alanine aminotransferase or as-
partate aminotransferase values are not available as part
of routine care, a blood sample will be obtained after
informed consent but before randomisation. Creatinine
kinase, alanine aminotransferase and aspartate aminotrans-
ferase values may be obtained up to 48 hours prior to
randomisation).Power and sample size estimate
Mean NET production in CAP-associated sepsis patients
is suppressed down to 7,500 arbitrary units (AU) versus
13,200 (SD 2,432) AU in age-matched control neutrophils.
At day 4, levels remain suppressed at 8,200 AU (SD 5,100)
but, by day 7, patient neutrophils have increased base-
line NET production almost back to normal (11,500 AU
(SD 6,100), P = 0.9) versus normal matched controls. If
we assume that statin treatment in vivo has a similar
magnitude of effect as it does in vitro on elderly patient
neutrophils (+80% NET production), then 18 patients in
each arm would be needed to increase NET production
by 5,000 AU from day 0 to day 4 with a power of 0.8,
P = 0.05. For 90% power we would need 23 patients in
each arm. To allow for drop outs due to death and so
forth, we intend to recruit 30 patients in each arm. Based
on our other preliminary data with 23 patients completing
each arm, we would have an 80% power to detect sig-
nificant increases in both chemotactic velocity (effect
size +0.5, ±35%) and ROS production (effect size ±57%).
For in vitro work on healthy elderly patient neutrophils we
typically require 6 to 8 patient samples for mechanistic
studies so these patient numbers should be adequate for
additional mechanistic work.
Trial conduct
Approach to patients and obtaining informed consent
Patients will be identified on the daily consultant ward
rounds that take place on the 40-bed clinical decision
unit and 80-bed ICU at the QEHB (approximately 60 to
70 daily admissions). Eligible patients may only be included
in the trial after obtaining written informed consent.
Where necessary, informed consent may be sought
from the patient’s personal legal representative who may
be a relative or close friend. If the patient is unable to
give informed consent and no personal legal representa-
tive is immediately available, a senior doctor (consultant
or registrar) who is not connected with the trial may act
as professional legal representative.
A copy of the signed informed consent form will be
placed in the patients’ medical records and the originals
will be retained by the personal legal representative and
by the Principal Investigator in the investigator site file.
Randomisation and drug/placebo supply
The trial drug (Simvastatin, 80 mg; trade name Accord)
and matching placebo will be manufactured by Sharp
Clinical Services Ltd (Crickhowell, UK) according to prin-
ciples of good manufacturing pratice. Matching IMPs will
be supplied and packaged according to the randomisation
sequence by Sharpe Clinical Services and delivered to the
QEHB pharmacy. Patients will be randomised sequentially
by allocating them to the next numbered treatment pack
held in the QEHB pharmacy.
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Subjects will receive either 80 mg simvastatin or placebo
once daily for 7 days or until hospital discharge, whichever
is shorter. The first dose of study drug will be administered
as soon as possible, ideally within 4 hours of randomisation
and all subsequent doses given each morning starting on the
following calendar day. The drug will be administered by
qualified medical or nursing staff. If patients exceed the liver
function test, renal or creatinine kinase entry criteria during
drug treatment, IMP administration will be withdrawn.
Concomitant medications
Patients taking the following medications are not eligible
for participation in the study:
 Current or recent statin use within 1 month.
 Taking itraconazole, ketoconazole, HIV protease
inhibitors, nefazodone, ciclosporin, amiodarone,
verapamil or diltiazem, fibric acid derivatives (except
fenofibrate) or danazol.
Severely ill pneumonia patients are usually treated with a
combination of intravenous penicillin and a macrolide anti-
biotic, typically clarithromycin 500 mg twice a day in our
trust. If we were to exclude patients who were taking clari-
thromycin, the trial would therefore only be able to enrol
patients with mild disease or those known to be intolerant
of macrolides. This would be a significant barrier to recruit-
ment and limit the generalizability of any finding of the
study to the general population. We will therefore not ex-
clude patients who are receiving concomitant clarithromycin
or erythromycin from this study.
Post-randomisation withdrawals and exclusions
Patients may withdraw or be withdrawn (by the personal
legal representative or professional legal representative) from
the trial at any time without prejudice. Data recorded up to
the point of withdrawal will be included in the trial analysis
unless consent to use their data has also been withdrawn. If
a patient or legal representative withdraws consent during
trial treatment, the trial drug will be stopped but permission
will be sought to access medical records to collect data re-
lated to the trail as per the protocol until the end of the trial.
Blinding/unblinding
All personnel involved in the trial, including patients, clinical
staff and research/trial staff, will be unaware of the arm of
the study to which the patient is allocated during trial par-
ticipation. Active and placebo treatment packs of the IMP
will be identical in packaging, appearance and contents. The
protocol allows for emergency unblinding in the event of
serious concerns about patient safety. In the unlikely event
that unblinding is required the local investigator will discuss
this with the chief investigator. All events will be logged.Monitoring and reporting adverse events
All adverse events and serious adverse events, irrespect-
ive of the causal relationship with the trial medications,
will be reported to the chief investigator within 24 hours
of awareness by the investigator. The chief investigator
will inform the sponsor and regulatory authorities. As
the IMPs used in this study are licensed in the UK, the
expected serious adverse reactions (SARs) will be re-
corded on the case report form.
Data collection
Data will be collected on individual case report forms,
designed and utilised by the research team to record pa-
tient data until hospital discharge. Submitted data will
be anonymised and data stored securely against un-
authorised access and accidental loss. Data collected will
include demographic details, as well as physiological and
ventilator variables that will act as indicators of disease
severity. If the subject remains in hospital at 28 or
90 days, survival at these time points will be recorded by
research staff.
Statistical analysis plan
Data will be analysed with the help of a trial statistician.
Data will be analysed using SPSS for windows 17.0
(IBM, NY, USA). A detailed analysis plan will be devel-
oped during the trial prior to commencement of analysis.
In brief, for continuously distributed data, differences be-
tween groups will be tested using independent samples
t-tests with transformations of variables to normality if
appropriate or non-parametric equivalents. Chi-squared
tests (or Fishers Exact tests) will be used for categorical
variables. A P value of 0.05 will be considered as signifi-
cant. We will test for significant correlations between
changes in the biological markers using standard methods.
The treatment effect will be analysed on an intention-to-
treat basis. For the further examination of relationships
between a binary variable and known explanatory vari-
ables, the following tests will be applied as appropriate.
Logistic regression will be used to provide the estimated
risk ratios for the treatment effect with associated 95%
confidence intervals. Time to event outcomes such as dur-
ation of ventilation or duration of hospital stay will be
analysed by survival methods and reported as hazard ra-
tios and 95% confidence intervals. A single final analysis is
planned at the end of the trial.
Trial organisation/oversight
Trial oversight will be provided by a Trial Steering
Committee comprising investigators, clinicians and trial-
ists. An independent data monitoring committee will
monitor the safety of participants enrolled in the trial
through regular review of adverse event reports. An in-
terim analysis of efficacy is not planned.
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Preliminary data on which this study is based suggests a
significant role of neutrophil immune-paralysis in the
development and progression of sepsis, a process that
may be amenable to correction by simvastatin. This
study will investigate the ability of in vivo simvastatin
therapy to modulate neutrophil anti-microbial functions
in CAP-associated sepsis and ultimately improve patient
outcomes.
Trial status
Patient recruitment commenced in December 2013 and
is expected to continue for 18 months with patient re-
cruitment ending in April 2015.
Additional file
Additional file 1: Methods. Full methods for analysis of primary and
secondary outcomes.
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